Trial intelligence / Profile preview

Dexelvucitabine versus lamivudine with optimized background therapy in treatment-experienced HIV-1 infection

2006-000096-16Phase 2Completed

Sponsor: Incyte
Start: Feb 2006
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, double-blind trial of dexelvucitabine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Incyte. Primary endpoint: Virologic response at Week 24. Started Feb 2006; status: completed.

Drugs

dexelvucitabine

Conditions

Human immunodeficiency virus infection type 1

Beyond the preview

Go deeper on 2006-000096-16.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-000096-16.